Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis

Delewi, Ronak; Hirsch, Alexander; Tijssen, Jan G.P.; Schächinger, Volker; Wojakowski, Wojciech; Roncalli, Jérôme; Aakhus, Svend; Erbs, Sandra; Aßmus, Birgit; Tendera, Michał; Turan, R.G.; Corti, Roberto; Henry, Timothy D.; Lemarchand, Patricia; Lunde, Ketil; Cao, Feng; Huikuri, Heikki V.; Sürder, Daniel; Simari, Robert D.; Janssens, Stefan; Wollert, Kai C.; Plewka, Michał; Grajek, Stefan; Traverse, Jay H.; Zijlstra, Felix; Piek, Jan J.

doi:10.1093/eurheartj/eht372

Cited by 128 publications

(102 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, there is growing evidence that patient characteristics, such as disease state, co-morbidities, co-medications and cardiovascular risk factors, critically influence the therapeutic outcome of SC application [99,385,520]. This finding clearly demands the implementation of personalized cardiac SC therapies in which the selection of SC source, modification and application is subjected to these individual characteristics [525].…”

Section: Resultsmentioning

confidence: 99%

“…A collaborative meta-analysis of randomized clinical trials revealed that younger patients and patients with a lower LVEF at baseline derived superior therapeutic benefit from intracoronary BM-derievd cell therapy [385]. These results were confirmed in a post hoc analysis of the REPAIR-AMI trial (NCT00279175) suggesting that higher age is associated with lower treatment benefit, while higher weight and massive initial functional loss are associated with enhanced response to BM-derived MNC therapy [520].…”

Section: Personalized Sc Therapymentioning

confidence: 93%

See 1 more Smart Citation

Stem Cell Therapy in Heart Diseases – Cell Types, Mechanisms and Improvement Strategies

Müller

Lemcke

Dávid

2018

Cell Physiol Biochem

161

140

View full text Add to dashboard Cite

A large number of clinical trials have shown stem cell therapy to be a promising therapeutic approach for the treatment of cardiovascular diseases. Since the first transplantation into human patients, several stem cell types have been applied in this field, including bone marrow derived stem cells, cardiac progenitors as well as embryonic stem cells and their derivatives. However, results obtained from clinical studies are inconsistent and stem cell-based improvement of heart performance and cardiac remodeling was found to be quite limited. In order to optimize stem cell efficiency, it is crucial to elucidate the underlying mechanisms mediating the beneficial effects of stem cell transplantation. Based on these mechanisms, researchers have developed different improvement strategies to boost the potency of stem cell repair and to generate the “next generation” of stem cell therapeutics. Moreover, since cardiovascular diseases are complex disorders including several disease patterns and pathologic mechanisms it may be difficult to provide a uniform therapeutic intervention for all subgroups of patients. Therefore, future strategies should aim at more personalized SC therapies in which individual disease parameters influence the selection of optimal cell type, dosage and delivery approach.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Personalized Sc Therapymentioning

confidence: 93%

Stem Cell Therapy in Heart Diseases – Cell Types, Mechanisms and Improvement Strategies

Müller

Lemcke

Dávid

2018

Cell Physiol Biochem

161

140

View full text Add to dashboard Cite

show abstract

“…Although the study design varied among reports, overall results revealed that bone marrow cell infusion might provide functional benefits in patients with myocardial infarction or refractory angina [23][24][25][26][27]. The promising nature of these findings has encouraged clinicians to continue the use of cardiac cell therapies in patients, at least until any contradictory evidence is reported.…”

Section: Meta-analysis Results Of Bone Marrow Cell Therapy For Ischemmentioning

confidence: 99%

Challenges to success in heart failure: Cardiac cell therapies in patients with heart diseases

Ito

Sano

2016

Journal of Cardiology

View full text Add to dashboard Cite

Heart failure remains the leading cause of death worldwide, and is a burgeoning problem in public health due to the limited capacity of postnatal hearts to self-renew. The pathophysiological changes in injured hearts can sometimes be manifested as scar formation or myocardial degradation, rather than supplemental muscle regeneration to replenish lost tissue during the healing processes. Stem cell therapies have been investigated as a possible treatment approach for children and adults with potentially fatal cardiovascular disease that does not respond to current medical therapies. Although the heart is one of the least regenerative organs in mammals, discoveries made during the past few decades have improved our understanding of cardiac development and resident stem/progenitor pools, which may be lineage-restricted subpopulations during the post-neonatal stage of cardiac morphogenesis. Recently, investigation has specifically focused on factors that activate either endogenous progenitor cells or preexisting cardiomyocytes, to regenerate cardiovascular cells and replace the damaged heart tissues. The discovery of induced pluripotent stem cells has advanced our technological capability to direct cardiac reprogramming by essential factors that are crucial for heart field completion in each stage. Cardiac tissue engineering technology has recently shown progress in generating myocardial tissue on human native cardiac extracellular matrix scaffolds. This review summarizes recent advances in the field of cardiac cell therapies with an emphasis on cellular mechanisms, such as bone marrow stem cells and cardiac progenitor cells, which show the high potential for success in preclinical and clinical meta-analysis studies. Expanding our current understanding of mechanisms of self-renewal in the neonatal mammalian heart may lead to the development of novel cardiovascular regenerative medicines for pediatric heart diseases.

show abstract

“…Однако мы не установили влияния трансплантации CD133 + ККМ при ОИМ на показа-тели локальной и глобальной сократительной функ-ции ЛЖ. Согласно данным последних мета-анализов исследований по данной тематике при транспланта-ции аутологичных мононуклеарных ККМ в сроки до 7 суток и в количестве более 10 8 и у пациентов с выра-женной дисфункцией ЛЖ также наблюдалось весьма скромное влияние на фракцию выброса ЛЖ, достига-лось ее повышение в среднем лишь на 3% [6,7,13]. Следует также отметить, что основной конечной точкой во многих исследованиях являлась динамика фракции выброса ЛЖ.…”

Section: таблица 2 конечные точки и показатели безопасности м [Ci]unclassified

Long Term Clinical Results of Autologous Cd133+ Bone Marrow Cells Transplantation in St Elevation Myocardial Infarction Patients

Киргизова¹,

Рябов²,

Суслова³

et al. 2016

Russ J Cardiol

View full text Add to dashboard Cite

Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis

Abstract: Intracoronary BMC infusion is associated with improvement of LV function and remodelling in patients after ST-segment elevation myocardial infarction. Younger patients and patients with a more severely depressed LVEF at baseline derived most benefit from this adjunctive therapy.

Cited by 128 publications

References 37 publications

Stem Cell Therapy in Heart Diseases – Cell Types, Mechanisms and Improvement Strategies

Stem Cell Therapy in Heart Diseases – Cell Types, Mechanisms and Improvement Strategies

Challenges to success in heart failure: Cardiac cell therapies in patients with heart diseases

Long Term Clinical Results of Autologous Cd133+ Bone Marrow Cells Transplantation in St Elevation Myocardial Infarction Patients

Contact Info

Product

Resources

About